Literature DB >> 29951199

C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors.

Brian I Carr1, Hikmet Akkiz2, Vito Guerra3, Oguz Üsküdar4, Sedef Kuran4, Ümit Karaoğullarından4, Salih Tokmak4, Tuğsan Ballı4, Abdulalh Ülkü4, Tolga Akçam4, Anıl Delik4, Burcu Arslan4, Figen Doran4, Kendal Yalçın5, Engin Altntaş6, Ayşegül Özakyol7, Mehmet Yücesoy8, Halil İbrahim Bahçeci9, Kamil Yalçın Polat10, Nazım Ekinci5, Halis Şimşek11, Necat Örmeci12, Abdulalh Sonsuz13, Mehmet Demir14, Murat Kılıç15, Ahmet Uygun16, Ali Demir17, Sezai Yilmaz18, Yaman Tokat19.   

Abstract

C-reactive protein (CRP) is a blood marker for inflammation and is an independent prognostic factor for many human cancers. Combined with albumin levels, it forms the basis of the Glasgow Index for cancer prognosis. We reviewed the literature on CRP and HCC and also evaluated blood CRP levels and combination CRP plus albumin levels in a large HCC cohort. In order to understand the prognostic significance of CRP, we retrospectively examined a large HCC cohort and examined the relationship of CRP levels to tumor parameters. We report, that CRP alone and CRP plus albumin combined as well, significantly correlated with parameters of HCC aggressiveness, such as maximum tumor dimension (MTD), portal vein thrombosis (PVT) and blood alpha-fetoprotein (AFP) levels, both as individual parameters and all parameters together (Aggressiveness Index). This extends current thinking, to suggest a possible explanation for the usefulness of blood CRP levels in HCC prognostication.

Entities:  

Keywords:  C-reactive protein; HCC; aggressiveness

Year:  2018        PMID: 29951199      PMCID: PMC6016854          DOI: 10.4172/clinical-practice.1000409

Source DB:  PubMed          Journal:  Clin Pract (Lond)        ISSN: 2044-9038


  62 in total

1.  Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma.

Authors:  Matthew D Taussig; Mary Ellen Irene Koran; Samdeep K Mouli; Asma Ahmad; Sunil Geevarghese; Jennifer C Baker; Andrew J Lipnik; Fil Banovac; Daniel B Brown
Journal:  HPB (Oxford)       Date:  2017-02-10       Impact factor: 3.647

2.  Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.

Authors:  Qing Pang; Lei Zhou; Kai Qu; Rui-Xia Cui; Hao Jin; Hui-Chun Liu
Journal:  Eur J Gastroenterol Hepatol       Date:  2018-01       Impact factor: 2.566

3.  Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Authors:  Tanya B Dorff; Bryan Goldman; Jacek K Pinski; Philip C Mack; Primo N Lara; Peter J Van Veldhuizen; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha H A Hussain
Journal:  Clin Cancer Res       Date:  2010-05-18       Impact factor: 12.531

4.  A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI).

Authors:  David J Pinato; Justin Stebbing; Mitsuru Ishizuka; Shahid A Khan; Harpreet S Wasan; Bernard V North; Keiichi Kubota; Rohini Sharma
Journal:  J Hepatol       Date:  2012-06-23       Impact factor: 25.083

5.  Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors.

Authors:  Daria Leali; Patrizia Alessi; Daniela Coltrini; Roberto Ronca; Michela Corsini; Giorgia Nardo; Stefano Indraccolo; Marco Presta
Journal:  Mol Cancer Ther       Date:  2011-07-15       Impact factor: 6.261

6.  Biosynthesis of human C-reactive protein in cultured hepatoma cells is induced by a monocyte factor(s) other than interleukin-1.

Authors:  N D Goldman; T Y Liu
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

7.  C-reactive protein inhibits expression of N-cadherin and ZEB-1 in murine colon adenocarcinoma.

Authors:  Satoshi Kudo; Hajime Saito; Satoru Motoyama; Tomohiko Sasaki; Kazuhiro Imai; Hayato Konno; Shinogu Takashima; Maiko Atari; Yusuke Sato; Yoshihiro Minamiya
Journal:  Tumour Biol       Date:  2015-04-13

8.  Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.

Authors:  Roberto Ronca; Patrizia Alessi; Daniela Coltrini; Emanuela Di Salle; Arianna Giacomini; Daria Leali; Michela Corsini; Mirella Belleri; Chiara Tobia; Cecilia Garlanda; Elisa Bonomi; Regina Tardanico; William Vermi; Marco Presta
Journal:  J Pathol       Date:  2013-06       Impact factor: 7.996

9.  A Hepatocellular Carcinoma Aggressiveness Index and Its Relationship to Liver Enzyme Levels.

Authors:  Brian I Carr; Vito Guerra
Journal:  Oncology       Date:  2016-03-15       Impact factor: 2.935

10.  Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis.

Authors:  Li-Na Ma; Xiao-Yan Liu; Zhen-Hui Lu; Li-Gang Wu; Yuan-Yuan Tang; Xia Luo; Yan-Chao Hu; Ting-Ting Yan; Qi Wang; Xiang-Chun Ding; Yan Xie
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

View more
  7 in total

1.  Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios predict tumor size and survival in HCC patients: Retrospective study.

Authors:  Aslı Suner; Brian I Carr
Journal:  Ann Med Surg (Lond)       Date:  2020-09-06

2.  Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.

Authors:  Hikmet Akkiz; Brian I Carr; Harika G Bag; Ümit Karaoğullarından; Kendal Yalçın; Nazim Ekin; Ayşegül Özakyol; Engin Altıntaş; Hatice Y Balaban; Halis Şimşek; Ahmet Uyanıkoğlu; Ayhan Balkan; Sedef Kuran; Oğuz Üsküdar; Yakup Ülger; Burak Güney; Anil Delik
Journal:  Int J Clin Pract       Date:  2020-12-12       Impact factor: 2.503

3.  CRP is a superior and prognostically significant inflammation biomarker for hepatocellular cancer patients treated by liver transplantation.

Authors:  Brian I Carr; Volkan Ince; Harika Gozukara Bag; Sertac Usta; Veysel Ersan; Burak Isik; Sezai Yilmaz
Journal:  Clin Pract (Lond)       Date:  2021

Review 4.  C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights.

Authors:  Peter C Hart; Ibraheem M Rajab; May Alebraheem; Lawrence A Potempa
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

5.  Dynamic Nomogram for Predicting Macrovascular Invasion of Patients with Unresectable Hepatocellular Carcinoma after Transarterial Chemoembolization.

Authors:  Huiwen Yan; Xinhui Wang; Dongdong Zhou; Peng Wang; Zhiyun Yang
Journal:  J Cancer       Date:  2022-03-28       Impact factor: 4.207

6.  Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes.

Authors:  B I Carr; V Guerra; R Donghia; S Yilmaz
Journal:  Ann Med Surg (Lond)       Date:  2021-06-02

7.  Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework.

Authors:  Phyllis Chan; Mathilde Marchand; Kenta Yoshida; Shweta Vadhavkar; Nina Wang; Alyse Lin; Benjamin Wu; Marcus Ballinger; Nitzan Sternheim; Jin Y Jin; René Bruno
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.